Sign In
Buy HROW
$42.78
+0.370 (+0.87%)
At Close: Jun 23, 2026
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
11:51am, Thursday, 11'th Jun 2026
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.
Harrow Adds Another Piece To Ophthalmology Strategy
11:42am, Thursday, 11'th Jun 2026
Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic ey
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (
Harrow to Present at William Blair's 46th Annual Growth Stock Conference
07:00am, Wednesday, 27'th May 2026
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present a
HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations
10:13am, Wednesday, 13'th May 2026
MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
02:30pm, Tuesday, 12'th May 2026
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
Harrow Q1 Earnings Call Highlights
11:11am, Tuesday, 12'th May 2026
Harrow NASDAQ: HROW executives said the company's first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emp
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
07:06pm, Monday, 11'th May 2026
Harrow (HROW) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.38 per share a year ago.
Harrow Announces First Quarter 2026 Financial Results
04:05pm, Monday, 11'th May 2026
First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
11:00am, Monday, 04'th May 2026
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
07:00am, Monday, 27'th Apr 2026
NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its fina
State of Alaska Department of Revenue Acquires 14,065 Shares of Harrow, Inc. $HROW
04:30am, Thursday, 23'rd Apr 2026
State of Alaska Department of Revenue lifted its holdings in shares of Harrow, Inc. (NASDAQ: HROW) by 807.4% in the fourth quarter, according to the company in its most recent disclosure with the Secu
Harrow: Now Is The Buy Time
07:30am, Monday, 20'th Apr 2026
Harrow has delivered a decade-long 40% CAGR in revenue, with robust operating leverage and EBITDA margin expansion. Seasonal weakness in Q1 consistently creates compelling entry points, with share pri
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
07:00am, Thursday, 16'th Apr 2026
NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclon
LogiCare3PL Selected as Distribution Partner by Harrow
10:30am, Tuesday, 14'th Apr 2026
OLIVE BRANCH, Miss., April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic disea
